Compare PROP & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PROP | ACOG |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.6M | 110.4M |
| IPO Year | 2008 | N/A |
| Metric | PROP | ACOG |
|---|---|---|
| Price | $0.88 | $5.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $6.75 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 3.2M | 33.9K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,939,000.00 | N/A |
| Revenue This Year | $81.83 | $139.22 |
| Revenue Next Year | $18.00 | $134.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $0.77 | $4.50 |
| 52 Week High | $4.33 | $10.88 |
| Indicator | PROP | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 37.81 | 48.73 |
| Support Level | N/A | $5.05 |
| Resistance Level | $1.93 | $6.59 |
| Average True Range (ATR) | 0.10 | 0.41 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 22.74 | 57.39 |
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.